Wednesday, 17 Oct 2018

You are here

Apremilast Continues to Look Good in Behcet's Disease

The 2018 American Academy of Dermatology (AAD) Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.

The RELIEF trial studied 207 patients who were randomized to apremilast 30 mg BID or placebo. The trial’s primary endpoint was the area under the curve (AUC) for the number of oral ulcers at week 12.

The AUC was significantly for apremilast versus placebo (129.5 vs. 222.1; P<0.0001). Significant improvements were also seen with apremilast in multiple secondary endpoints, including oral ulcer pain (P<0.0001), overall disease activity (Behçet’s Syndrome Activity Score: P<0.0001; Behçet’s Disease Current Activity Index: P=0.0335) and quality of life (P=0.0003).

Diarrhea was the most frequent adverse event (41.3 percent with apremilast, 19.4 percent for placebo). Otherwise the safety profile was consistent with the known safety profile of apremilast.

Celgene intends to submit its supplemental New Drug Applications for apremilast in active Behçet’s Disease with oral ulcers in the U.S. in the second half of this year.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hip and Knee Replacements Monitored by Smart Watch

Reuters reports that patients with hip or knee replacements will now be followed for progress using their Apple watches.

A multi-site study involving medical facilities from Massachusetts, California, Colorado and Michigan will receive stats including heart rate, steps taken and standing hours from patients waiting for or recovering from hip and knee replacement surgery.

NSAIDs OK for Certain High-Risk Groups?

Some patients typically contraindicated for prescription nonsteroidal anti-inflammatory drug (NSAID) use may be able to take them with no increased risk of harm, according to a large observational study.

Physical Therapy Equals Arthroscopic Surgery in Meniscal Tears

Several new trials suggest that conservative management may be as efficacious as arthroscopic surgery in patients with meniscal tears, thus contributing to the trend of fewer arthroscopic surgeries. A new trial of patients with nonobstructive meniscal tears shows no significant difference in 2 year outcomes between physical therapy and early arthroscopic partial meniscectomy.

Activity Trackers May be Helpful in Arthritis Patients

Use of wearable activity trackers was associated with increases in the number of daily steps among individuals with rheumatic and musculoskeletal disorders, a meta-analysis found.

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.